Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150981 | 0.93 | MAPT (0.53) | MAPTOPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL7553789 | 0.93 | MAPT (0.53) | MAPTOPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL29544382 | 0.91 | MME (0.44) | MAPTOPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL30285977 | 0.90 | OPRD1 (0.49) | MAPTOPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL30661446 | 0.90 | OPRD1 (0.53) | MAPTOPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL30661448 | 0.90 | OPRD1 (0.53) | MAPTOPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL31182817 | 0.89 | OPRD1 (0.46) | MAPTOPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL29421932 | 0.89 | OPRD1 (0.43) | MAPTOPRD1OPRM1OPRK1MME | |
| SCHEMBL30999832 | 0.87 | MME (0.54) | MAPTOPRD1OPRM1OPRK1MME | |
| SCHEMBL30662551 | 0.86 | CA2 (0.47) | MAPTMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248564-B | Active peptide having tyrosinase inhibitory activity | 渤海大学 | 2022-02-11 | — | — | CN | claimed |
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | EYEBIO KOREA (KR) | 2025-09-30 | — | — | US | disclosed |
| CN-119751647-A | Recombinant type IV collagen and preparation method and application thereof | 江苏创健医疗科技股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4483959-A2 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2025-01-01 | — | — | EP | disclosed |
| EP-3974441-B1 | PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-10-24 | — | — | US | disclosed |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-3974441-A1 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2022-03-30 | — | — | EP | disclosed |
| CN-114163516-A | Collagen source tyrosinase inhibitory peptide and preparation method and application thereof | 中国水产科学研究院南海水产研究所 | 2022-03-11 | — | — | CN | disclosed |
| CN-113248564-B | Active peptide having tyrosinase inhibitory activity | 渤海大学 | 2022-02-11 | — | — | CN | disclosed |
| CN-113248564-B | Active peptide having tyrosinase inhibitory activity | 渤海大学 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | VIP, FURIN, IAPP | MAPT 1317/4885OPRD1 3656/4885OPRM1 4051/4885 |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | MAPT 1694/4885OPRD1 3582/4885OPRM1 4016/4885 |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | MAPT 1694/4885OPRD1 3582/4885OPRM1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.